teva share recov follow cfo departur news focu remain
teva share mostli recov follow anoth
sell-off morn unexpect news cfo michael mcclellan decid
step person reason creat uncertainti come terribl
time think import item ceo kare schultz remain fulli
commit lead co reach financi target year
includ revenu ebitda think
second import item like upcom multi-district litig mdl
idc btig estim compani document
million except per share amount
schedul heard ohio later fall recent call host
attorney scott willoughbi view us district court judg polster
interest get outcom might get fund addict center
rehab clinic quickli possibl ultim requir settlement reach
view next mileston opioid litig decis state
oklahoma sort financi damag johnson johnson rate
may face maintain neutral rate teva share
morn teva report revenu vs estimate
adj ep in-lin forecast teva continu face
headwind copaxon sale eros key brand product launch includ
austedo ajovi steadili progress call manag highlight
austedo ramp continu co reiter comfort level
target year ajovi sale ramp may slow
rais austedo sale forecast
lower ajovi sale estim
teva reiter financi guidanc revenu
ebitda current net debt balanc leav
co tough financi posit especi futur opioid litig liabil
go well excess billion dollar teva remain challeng
posit head year end think import driver share
upcom mdl case whether settlement deal reach
debt repay remain key focu co finish net debt
posit paid juli
valuat maintain neutral rate teva share
maintain neutral rate teva share base challeng fundament co gener busi
sale declin copaxon high net debt level potenti addit futur liabil associ
outstand opioid gener price lawsuit
continu launch brand product includ austedo treatment
tardiv dyskinesia chorea associ huntington diseas ajovi
prevent migrain
execut co cost save program expect lead
reduc expens
estimate revenu ep
gener competit copaxon sale declin major headwind
revenu cash flow exceed estim
stronger expect ajovi and/or austedo sale
co abl pay debt faster expect
lead global manufactur
gener specialti
nearli everi therapeut area
portfolio product
found co
headquart petach tikva
weaker expect gener segment sale
weaker expect ajovi and/or austedo sale
acceler copaxon sale eros due multipl gener
greater expect liabil outstand opioid case
case includ mdl teva also defend
morn teva report revenu vs estimate adj ep in-lin forecast
teva continu face headwind copaxon sale eros key brand product launch includ austedo
ajovi steadili progress call manag highlight austedo ramp continu co reiter
comfort level target year ajovi sale ramp may slow
rais austedo sale forecast lower ajovi sale estim
teva reiter financi guidanc revenu ebitda
current net debt balanc leav co tough financi posit especi futur opioid litig liabil
go well excess billion dollar
tabl includ teva financi guidanc detail estimate
copaxon treatment relapsing-remit ms sale continu erod due gener competit current
two gener version copaxon us market buy pt sandoz novarti nv
ajovi sale forecast launch benefit potenti auto-
teva ajovi gain fda approv prevent episod chronic migrain last septemb
rate emgal galcenezumab follow suit three approv cgrp-antagonist drug prevent
migrain headach teva report lower expect ajovi sale vs estimate formulari access
cgrp monoclon continu expand two-third patient commerci health insur
access ajovi
still earli launch believ new class cgrp-antagonist migrain treatment steadili gain
traction total prescript volum steadili increas accord symphoni health data teva ajovi lilli
emgal gain share market drug current hold share weekli prescript
believ migrain suffer us could elig seek treatment
austedo approv april treatment chorea associ huntington diseas rare inherit
relentlessli progress ultim fatal diseas mark degener nerv cell brain caus movement
jerk swallow cognit psychiatr disord diseas affect patient us august austedo
approv treatment tardiv dyskinesia adult tardiv dyskinesia neurolog movement disord
character involuntari movement face lip tongu lip trunk extrem usual develop patient
treat mental ill medic
estimate austedo deutetrabenazin treatment chorea associ huntington diseas sale
potenti averag monthli volum grew sequenti increas prescript vs
austedo like benefit broad payor coverag almost patient commerci insur access
drug
product black box warn depress suicid similar tetrabenazin avail gener
think austedo may advantag side effect profil includ lower rate depress vs
tetrabenazin somol vs akathisia vs
austedo orphan statu elig year exclus us
base stronger expect ramp up austedo sale estim
respect
austedo sale exceed forecast
ltd teva earn model gross oper expens pre-tax adj incom non-control interests- net average share adj analysisgross analysistot earn per co report btig
btig cover compani mention report
appendix analyst certif import disclosur
